急诊人工肝治疗乙型病毒性肝炎相关慢加急性肝衰竭预后的研究进展  

Progress on prognosis of hepatitis B virus related acute-on-chronic liver failure with artificial liver support system therapy in emergency department

作　　者：倪小雨 孙瑶 王兴磊[1,2] 张蜀 NI Xiaoyu;SUN Yao;WANG Xinglei;ZHANG Shu(Department of Emergency,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P.R.China;West China School of Medicine,Sichuan University,Chengdu,Sichuan 610041,P.R.China)

机构地区：[1]四川大学华西医院急诊科,成都610041 [2]四川大学华西临床医学院,成都610041

出　　处：《华西医学》2021年第11期1603-1607,共5页West China Medical Journal

基　　金：四川大学华西医院学科发展1·3·5工程项目(ZYJC21055)。

摘　　要：乙型病毒性肝炎相关慢加急肝衰竭(hepatitis B virus related acute-on-chronic liver failure,HBVACLF)具有进展快和死亡率高的特点,人工肝支持系统(artificial liver support system,ALSS)治疗该类患者的疗效远优于标准药物治疗,在急诊HBV-ACLF中应用广泛。ALSS是利用体外机械或生物装置替代损伤的一部分肝功能,分为生物型、非生物型和混合型。目前缺乏统一的ALSS治疗HBV-ACLF预后敏感指标及公认的预后模型。该文对ALSS治疗HBV-ACLF预后评估的研究进展进行了综述,以期为临床医生和科研工作者提供参考。Hepatitis B virus related acute-on-chronic liver failure(HBV-ACLF)has the characteristics of rapid progress and high mortality.Artificial liver support system(ALSS)is far superior to standard drug therapy in the treatment of such patients,and is widely used in emergency.ALSS is the use of external mechanical or biological devices to replace a part of the damaged liver function,divided into bioartificial,non-bioartificial liver and a combination of the two.At present,there is no unified sensitive prognostic index and recognized prognostic model for HBV-ACLF in artificial liver treatment.This paper reviews the research progress of prognosis evaluation of ALSS in the treatment of HBV-ACLF,in order to provide reference for clinicians and researchers.

关 键 词：人工肝 乙型肝炎病毒 肝衰竭 预后 

分 类 号：R575.3[医药卫生—消化系统] R512.62[医药卫生—内科学]